Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2012

View Archived Issues

Novel inhibitors of GlyT1 designed in Japan

Roche reviews developments of first quarter 2012

Eisai divulges new suppressors of prostanoid signaling

Collaboration yields novel potential therapies for hepatitis C

Investigators in U.S. link desaturase to survival of patients with breast cancer

Potential new antidepressant has promising pharmacokinetic profile

Novel microRNA-based drug shows potential to treat liver cancer

Potent ROCK inhibitors with oncolytic potential identified in U.S.

Novel antimalarials identified through phenotypic whole-cell screening

New P2X7 receptor antagonists patented by Merck & Co.

Takeda and Metabolon to collaborate on targets/biomarkers

Rockland Immunochemicals and LIMR enter commercialization agreement

Five Prime Therapeutics and GSK collaborate on respiratory diseases

Michael J. Fox Foundation funds to-BBB Parkinson's disease research

Sucampo and Clinigen implement named-patient program for Amitiza

ME-3738 program discontinued

Celek Pharmaceuticals provides update on progress for CEL-031

Eisai presents PARP inhibitor with promising anticancer activity

Argyle Therapeutics out-licenses topical rosacea treatment candidate

Tengion plans IND submission for Neo-Kidney Augment

Pluristem receives clearance for phase II PLX-PAD trial

FDA issues complete response letter for Pliaglis sNDA

MSD launches antifungal drug in Japan

BMS and Janssen expand collaboration on TMC-435 and BMS-790052

Bayer Yakuhin launches anticoagulant tablet in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...